Search clinical trials for: Prasugrel Hydrochloride

Total 7357 results

Gyeongsang National University Hospital

Completed

Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome

Bleeding | Acute Coronary Syndrome | Platelet Thrombus

Korea, Republic of
University of Florida

Completed

Prasugrel Re-load Strategies

Coronary Artery Disease

United States
University of Milan

Completed

The Effect of Prasugrel on Bronchial Hyperreactivity and on Markers of Inflammation in Patients With Chronic Asthma (PRINA)

Chronic Asthma

Italy
Medstar Health Research Institute

Completed

The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel (SWITCH 600/60)

Acute Coronary Syndrome

United States
University of Florida

Completed

Pharmacological Effects of Crushing Prasugrel in STEMI Patients

Coronary Artery Disease

United States
Eli Lilly and Company
Daiichi Sankyo, Inc.

Completed

A Study of Prasugrel in Healthy Participants

Healthy Volunteers

United States
VA Office of Research and Development

Completed

Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis

Coronary Artery Bypass

United States
Azienda Ospedaliera Universitaria Integrata Verona
University of Milan

Unknown

Prasugrel in Severe COVID-19 Pneumonia (PARTISAN)

Thrombosis | COVID19

Italy
University of Patras

Completed

High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)

Platelet Reactivity

Greece
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company

Completed

Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)

Acute Coronary Syndrome (ACS)

Taiwan
Maasstad Hospital
Daiichi Sankyo, Inc.; MicroPort Orthopedics Inc.; Research Maatschap Cardiologen...

Completed

CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCI (CompareCrush)

Cardiovascular Diseases

Netherlands
Eli Lilly and Company

Completed

Study of Prasugrel in Korean Healthy Male Volunteers

Healthy Volunteers

Korea, Republic of
Eli Lilly and Company
Daiichi Sankyo Co., Ltd.

Completed

An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults

Anemia, Sickle Cell

United Kingdom
Eli Lilly and Company
Daiichi Sankyo, Inc.

Terminated

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Sickle Cell Disease

United Arab Emirates, Italy, United States, Egypt, United Kingdom, Belgium, Turkey, Brazil, Canada, Ghana, Kenya, Lebanon, Oman, Saudi Arabia
Rigshospitalet, Denmark

Completed

Time to Thrombocytic Inhibition After Supine and Upright Ingestion of Efient

ST-elevation Myocardial Infarction | Ischemic Heart Disease | Heart Disease

Denmark
Eli Lilly and Company
Daiichi Sankyo, Inc.

Completed

Prasugrel Versus Placebo in Adult Sickle Cell Disease

Sickle Cell Anemia

United States
Germano Di Sciascio
Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Department of Advanced... and other collaborators

Completed

Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study (PROMICRO-3)

Coronary Artery Disease

Belgium
Eli Lilly and Company

Completed

A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet

Sickle Cell Disease

United States
Research Maatschap Cardiologen Rotterdam Zuid
Abbott Medical Devices

Recruiting

Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients

ST Elevated Myocardial Infarction | Dual Antiplatelet Therapy

Netherlands, Germany, Italy
Eli Lilly and Company
Daiichi Sankyo Co., Ltd.

Completed

A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction (ACCOAST)

Acute Coronary Syndromes

Israel, Italy, Germany, Belgium, Poland, France, Austria, Netherlands, Turkey, Hungary, Lithuania, Romania, Canada, Slovakia, Czech Republic, Finland, Latvia, Portugal, Sweden
Eli Lilly and Company
Daiichi Sankyo, Inc.

Completed

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (Crescent)

Sickle Cell Disease

United States
Ottawa Heart Institute Research Corporation
Spartan Bioscience Inc.

Completed

ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (RAPID GENE)

Acute Coronary Syndrome | Percutaneous Coronary Intervention | Stable Coronary Artery Disease

Canada
Ottawa Heart Institute Research Corporation
Spartan Bioscience Inc.

Completed

Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI) (RAPID STEMI)

STEMI

Canada
David Antoniucci
A.R. CARD Onlus Foundation

Terminated

BLeeding Events and Maintenance DoSe of PraSugrel (BLESS)

Acute Coronary Syndrome | Adverse Reaction to Antiplatelet Agent

Italy
Asan Medical Center

Unknown

Clinical Trial to Characterize Pharmacokinetic-pharmacodynamic (PKPD) of Prasugrel 10 mg or 30 mg in Healthy Volunteers (PRAS-AM)

Healthy

Korea, Republic of
University Hospital, Geneva

Completed

Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel

Acquired Platelet Disorder

Switzerland
Elliot Israel, MD
Brigham and Women's Hospital

Completed

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin) (Aspirin)

Asthma, Aspirin-Induced | Aspirin Exacerbated Asthma

United States
Eli Lilly and Company
Daiichi Sankyo, Inc.

Completed

Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event (SWAP)

Acute Coronary Syndrome | Coronary Arteriosclerosis

United States
Università degli Studi di Ferrara

Completed

Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse (FABOLUS PRO)

ST Segment Elevation Myocardial Infarction

Italy
University of Pecs

Completed

Prasugrel Versus Clopidogrel to TREAT High Platelet Reactivity (TREAT-HPR)

Acute Coronary Syndrome

Hungary
Eli Lilly and Company

Completed

A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Heart Diseases | Cardiovascular Diseases

United States, Canada
Seoul National University Hospital
Boston Scientific Korea Co. Ltd; Dio; Terumo Corporation; Abbott

Unknown

Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)

Acute Coronary Syndrome

Korea, Republic of
Meditrix Corp
National University of Ireland, Galway, Ireland; Boston Scientific Japan K.K.; Fujita Health University

Recruiting

Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study (ASET-JAPAN)

Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary Syndrome

Japan, Ireland
Pedro A. Lemos
Imperial College London; Cardialysis B.V.

Unknown

Acetyl Salicylic Elimination Trial: The ASET Pilot Study (ASET)

Monotherapy After PCI

Brazil
Assistance Publique - Hôpitaux de Paris
Eli Lilly and Company; Daiichi Sankyo, Inc.; Stentys; Accumetrics, Inc.; Allies in...

Completed

Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel (ANTARCTIC)

Acute Coronary Syndrome

France
Daiichi Sankyo, Inc.
Eli Lilly and Company

Completed

Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease (SWAP-2)

Coronary Artery Disease

United Kingdom, United States
University of Patras

Completed

Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention

Coronary Artery Disease | Acute Coronary Syndrome

Greece
University of Patras

Completed

Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment

Coronary Artery Disease (CAD)

Greece
Hotel Dieu de France Hospital

Unknown

Ticagrelor and Endothelial Function

Antiplatelet Agents; Endothelial Function; Pleotropic Effects

Lebanon
Careggi Hospital

Completed

Rapid Activity of Platelet Inhibitor Drugs Study (RAPID)

ST-segment Elevation Myocardial Infarction

Italy
University of Patras

Completed

Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study

Coronary Artery Disease | Acute Coronary Syndrome

Greece
AORTICA Group

Completed

Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI (COMPARE)

ST Elevation Myocardial Infarction

Spain
Federal University of São Paulo

Completed

Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis (SAMPA)

Acute Coronary Syndrome | Platelet Function

Brazil
Deutsches Herzzentrum Muenchen

Unknown

Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing (ISAR ADAPT PF)

Coronary Heart Disease

Germany, Hungary
University of Patras

Completed

Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)

Platelet Reactivity

Greece
University of Patras

Completed

Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI) (PRO-GR-4)

Myocardial Infarction

Greece
University of Patras

Completed

Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis

Hemodialysis | Chronic Renal Failure

Greece
Assistance Publique Hopitaux De Marseille

Completed

Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention

Acute Coronary Syndromes

France
Gennaro Sardella

Completed

Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial (RESET GENE)

Acute Coronary Syndrome

Italy
University of Florida
Scott R. MacKenzie Foundation

Completed

Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI (SWAP-6)

Coronary Artery Disease | Acute Coronary Syndrome

United States

Search clinical trials for: Prasugrel Hydrochloride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations